

Peer Review

Review of: "A Novel Bispecific Antibody CVL006 Superior to AK112 for Dual Targeting of PD-L1 and VEGF in Cancer Therapy"

Alessandra Villa¹

1. Independent researcher

Dear Xiaokun Shen, dear Team,

The paper was pleasant to read, straight to the point, and with translational potential.

I may suggest a few complementary comments on the work.

In the background section, may I suggest modifying “combat cancer” to “fight cancer”?

Do you think that keeping the fully functional Fc could be a problem for safety/cytokine release?

Would you benchmark the Fc-wild type versus the Fc-silenced? Any toxicology study planned to dig deeper into this?

Can you please comment a bit more on why this CVL006 format was chosen? Were other formats considered, (e.g., VHH fusion to the C-terminal light chain, or fusion to the heavy chain)?

Maybe a technical issue on my PC, but supplementary figure 3 (SPR traces) is very low definition, almost not visible. May I suggest improving the quality? Also, regarding the SPR, can you add a comment on the coating density of the chip obtained with your bispecific?

Could you please comment on how the administered dose of CVL006 (mg/kg) was chosen?

Best regards,

Alessandra

Declarations

Potential competing interests: No potential competing interests to declare.